Zealand Pharma brings in $1B to drive development of obesity drugs

Zealand Pharma raised $1 billion through the sale of new shares as it looks to forge ahead with the development of a number of its obesity pipeline candidates. The company agreed to sell nearly 8.4 million shares at DKK 843 ($121) each, with the offering upsized from an earlier target of $900 million amid high demand.